三倍做多标普生物-Direxion(LABU)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LABU 三倍做多标普生物-Direxion

已收盘 07-30 16:00:00 EDT

248.79

+16.56

+7.13%

盘后251.00

+2.21+0.89%

19:59 EDT

最高250.93	最低227.27	成交量27.53万
今开231.01	昨收232.23	日振幅10.19%
总市值5.53亿	流通市值5.53亿	总股本222.45万
成交额6,581万	换手率12.38%	流通股本222.45万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"三倍做多标普生物-Direxion","latestPrice":248.79,"timestamp":1785441600000,"preClose":232.23,"halted":0,"volume":275287,"hourTrading":{"tag":"盘后","latestPrice":251,"preClose":248.79,"latestTime":"19:59 EDT","volume":6629,"amount":1657069.6739,"timestamp":1785455974359,"change":2.21,"changeRate":0.008883,"amplitude":0.019856},"delay":0,"changeRate":0.071308616457822,"floatShares":2224486,"shares":2224486,"eps":0,"marketStatus":"已收盘","change":16.56,"latestTime":"07-30 16:00:00 EDT","open":231.01,"high":250.9345,"low":227.2742,"amount":65806148.84007,"amplitude":0.101883,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1785484800000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":232.23,"sharesOutstanding":3024486,"nav":232.913,"aum":506465838.59,"dividendRate":0.004068,"bidAskSpread":0.004413,"preHourTrading":{"tag":"盘前","latestPrice":232.65,"preClose":232.23,"latestTime":"09:29 EDT","volume":3027,"amount":712925.3967,"timestamp":1785418196181,"change":0.42,"changeRate":0.001809,"amplitude":0.024114},"postHourTrading":{"tag":"盘后","latestPrice":251,"preClose":248.79,"latestTime":"19:59 EDT","volume":6629,"amount":1657069.6739,"timestamp":1785455974359,"change":2.21,"changeRate":0.008883,"amplitude":0.019856},"volumeRatio":0.866436,"impliedVol":1.0217,"impliedVolPercentile":0.8964},"requestUrl":"/m/hq/s/LABU","defaultTab":"news","newsList":[{"id":"2655806134","title":"强生（JNJ）抗头颈癌药物获FDA优先审查 拓展适应症迎来关键节点","url":"https://stock-news.laohu8.com/highlight/detail?id=2655806134","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655806134?lang=zh_cn&edition=full","pubTime":"2026-07-30 22:43","pubTimestamp":1785422625,"startTime":"0","endTime":"0","summary":"凭借优先审评通道，FDA审查周期将缩短至6个月，常规审批时长为10个月，有望加速这款双靶点皮下制剂落地。若头颈癌适应症顺利获批，将进一步拓宽产品收入空间，同时利好合作方Halozyme。市场持续等待FDA最终审批结论，跟踪该药物在实体瘤领域持续拓展潜力。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210625/ZGFjNmMxNjJiOWZlZTExMTI2OTIxOTcyMDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/ZGFjNmMxNjJiOWZlZTExMTI2OTIxOTcyMDA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303246","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0689472784.USD","BMED","LU0203345920.USD","LU0466842654.USD","IE00B1BXHZ80.USD","LU1162221912.USD","IHE","LU1032466523.USD","LU1280957306.USD","GDOC","JNJ","LABU","IXJ","IE00BJJMRZ35.SGD","XLV","JDOC","RXL","VHT","LU2129689431.USD","BK4550","LU1894683264.USD","LU1145028129.USD","MEDX","IE0001KFT4U8.USD","IE00BDGV0183.EUR","HALO","LU2602419157.SGD","BK4588","PJP","IE0034235303.USD","LU2403377893.USD","LU0994945656.USD","FFOX","FTXH","LU1261432733.SGD","LU0640476718.USD","IYH","LU2592432038.USD","LU1032955483.USD","BK4559","LU0098860793.USD","LU1043141123.HKD","LU2129689514.USD","TRUH","LU1043141396.HKD","LU1585245621.USD","LU2129689605.HKD","IE00B4R5TH58.HKD","LU0203347892.USD","FHLC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111809281","title":"医疗保健板块市场热议：赛诺菲新CEO布局受关注，PolyNovo现金流强劲，泰国医疗板块盈利疲软，GE HealthCare业绩超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1111809281","media":"投资观察","labels":["executive","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111809281?lang=zh_cn&edition=full","pubTime":"2026-07-30 16:22","pubTimestamp":1785399774,"startTime":"0","endTime":"0","summary":"在0742 GMT，Intron Health的分析师Naresh Chouhan和Dominic Rose发布报告指出，赛诺菲在迎来新任CEO后，其二季度财报充满了诸多变数。尽管赛诺菲将Dupixent在2030年的销售预期进行了上调，但却下调了疫苗业务的展望。消息公布后，赛诺菲股价下跌2.4%。1410 GMT，通用电气医疗公布其二季度营收为53亿美元，同比增长5.8%，超出华尔街的预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","XLV","BK4588","BK4585","XBI","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655898685","title":"石药集团(01093.HK)：CRB -701 (SYS 6002)用于口咽癌二线治疗的注册性临床试验获美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2655898685","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655898685?lang=zh_cn&edition=full","pubTime":"2026-07-29 20:35","pubTimestamp":1785328539,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","IBBQ","BK4585","IBBJ","LABU","PSYK","MDTX","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655898680","title":"石药集团(01093)：CRB -701 (SYS 6002)用于口咽癌二线治疗的注册性临床试验获美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2655898680","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655898680?lang=zh_cn&edition=full","pubTime":"2026-07-29 20:35","pubTimestamp":1785328539,"startTime":"0","endTime":"0","summary":"此前，美国FDA已就该产品治疗HNSCC及宫颈癌两项适应症，分别授予该药物两项快速通道资格认定。TEMPO-1为一项随机对照试验。Corbus预计将于2026年第三季度启动TEMPO-1的患者入组。美国FDA批准启动此项注册性试验，乃基于Corbus正在进行的该产品I/II期临床试验所获得的数据支持，该等数据近期已于2026年美国临床肿瘤学会年会上发布。目前，该研究随访仍在持续开展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1473723.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1951186391.HKD","LU0067412154.USD","MDTX","BK4585","LU1226287875.USD","BK4588","LU1807302812.USD","IE0008368742.USD","LU1152091754.HKD","LU1226287792.SGD","IE00BZ08YR35.GBP","IE00B031HY20.USD","IE0008369823.USD","LU1226287529.USD","IBBJ","LU0072913022.USD","HK0000165453.HKD","LU0314109678.HKD","BK1191","BK1515","IBBQ","IE00BZ08YS42.EUR","IE00B543WZ88.USD","SG9999004220.SGD","BMED","01093","LU1226288170.HKD","LU1993786604.SGD","BK1521","LU0140636845.USD","LU0326950275.SGD","PSYK","LU1813983027.USD","LU2039709279.SGD","LU1960683339.HKD","LU0880133367.SGD","LABU","LU1008478684.HKD","LU0501845795.SGD","LU1226288253.USD","IE00BZ08YT58.USD","KURE","LU1152091168.USD","IE00B5MMRT66.SGD","LU0315179316.USD","LU1328277881.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655865615","title":"石药创新：CRB-701获美国FDA批准启动二线OPSCC注册性临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2655865615","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655865615?lang=zh_cn&edition=full","pubTime":"2026-07-29 17:44","pubTimestamp":1785318279,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","LABU","PSYK","IBBJ","MDTX","BMED","BK4588","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101014982","title":"医疗保健板块综述：市场动态快讯","url":"https://stock-news.laohu8.com/highlight/detail?id=1101014982","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101014982?lang=zh_cn&edition=full","pubTime":"2026-07-29 16:25","pubTimestamp":1785313501,"startTime":"0","endTime":"0","summary":"0608 GMT - 伯恩斯坦分析师指出，依视路陆逊梯卡的投资故事仍是一场微妙的平衡。这家法意眼保健巨头在截至6月的季度里，销售增长略有放缓，但管理层对前景表示乐观，这得益于其与科技集团Meta在AI智能眼镜领域的合作。伯恩斯坦认为，这一品类应能确保该公司在未来一两年内交出稳健的业绩表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4581","XLV","XBI","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655831393","title":"英硅智能 ISM6331 获美国 FDA 快速通道资格，用于晚期间皮瘤治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2655831393","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655831393?lang=zh_cn&edition=full","pubTime":"2026-07-29 08:17","pubTimestamp":1785284261,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LABU","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654885615","title":"生物科技公司Capricor Therapeutics面临FDA质疑与证券欺诈调查 股价连续暴跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2654885615","media":"环球市场播报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654885615?lang=zh_cn&edition=full","pubTime":"2026-07-28 23:15","pubTimestamp":1785251700,"startTime":"0","endTime":"0","summary":"生物科技公司Capricor Therapeutics正面临严峻挑战，其股价近期大幅下挫——周一该股收盘重挫64.49%，周二早盘再跌逾15%。FDA审查人员对Capricor的核心候选药物deramiocel的疗效数据提出质疑，认为其关键性III期HOPE-3试验未能达到预设的主要和关键次要疗效终点。此外，多家律师事务所已对Capricor提起或正在调查证券欺诈集体诉讼。诉讼主要指控公司在2024年10月9日至2025年7月10日期间，就其获得FDA批准的可能性作出了虚假和误导性陈述，同时隐瞒了关于deramiocel安全性和有效性的不利事实。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-28/doc-inikksxz1845469.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159837","BK4581","LENZ","IBBJ","LABU","GDOC","HBImain","IEIH","BK4585","LNGR","BK4588","161027","MEDX","SYNB","AGNG","XBI","BK4007","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654000331","title":"美股医疗健康板块盘初走高，礼来、诺和诺德涨超1%，联合健康跟涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2654000331","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654000331?lang=zh_cn&edition=full","pubTime":"2026-07-28 21:35","pubTimestamp":1785245718,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0158827948.USD","LU0061475181.USD","LU2063271972.USD","LU0097036916.USD","LU1066053197.SGD","LU1506573853.SGD","IE00B19Z9P08.USD","LU2213496289.HKD","LU1267930573.SGD","LU2106854487.HKD","LU0553294199.USD","LU1974910355.USD","LU0943347566.SGD","LU0106261372.USD","LU1718418525.SGD","LU2468319806.SGD","IE00BJT1NW94.SGD","LU0432979614.USD","LU0738911758.USD","LU1084165304.USD","LU2237443895.HKD","LLYZ","LU2264538146.SGD","MEDX","LU0198837287.USD","IE00B19Z8X17.USD","LU0122379950.USD","LU1145028129.USD","LU1366192091.USD","IHF","LU0345770308.USD","LU2552382058.USD","BK4154","LU0109394709.USD","OZEM","WDNA","IE0004445015.USD","LU1066051811.HKD","CANC","LU0861579265.USD","LU2087625088.SGD","LU1093756168.USD","LU1074936037.SGD","ILDR","LU0211327993.USD","IE00BN29S564.USD","LU2089984988.USD","LU0128525689.USD","LU1868836757.USD","NVOH","IE00BK4W5L77.USD","LU0320765059.SGD","LU0203201768.USD","LU2361044865.SGD","BK4007","LU0882574055.USD","SGXZ81514606.USD","LU1674673691.USD","IE000M9KFDE8.USD","SG9999018865.SGD","BK4599","LU2133065610.SGD","LU1061106388.HKD","LU1064131342.USD","LU2361044949.HKD","LU0528227936.USD","LU2237443382.USD","SG9999015978.USD","IE00BJJMRY28.SGD","LU2360106947.USD","SG9999014906.USD","BK4566","LU1623119135.USD","IE00B7SZLL34.SGD","LU0256863902.USD","LU2461242641.AUD","LU0203202063.USD","LU2244417387.USD","TRUH","LU0557290698.USD","IE0001KFT4U8.USD","LU1057294990.SGD","LU0820562030.AUD","IE00BFSS7M15.SGD","LU2237443978.SGD","IE00BJJMRX11.SGD","LU2552382215.SGD","IE00BJLML261.HKD","FTXH","XLV","LU0058720904.USD","RXL","LU2896262040.SGD","IE00B1BXHZ80.USD","LU1983299246.USD","LU1720051108.HKD","IE00B775H168.HKD","LU1712237335.SGD","LU0109391861.USD","LU1868837136.USD","LU2602419157.SGD","LU0266013472.USD","LU0787776722.HKD","LU1035773651.USD","IE00BK4W5M84.HKD","LU0256863811.USD","LU0471298777.SGD","LU0708994859.HKD","LU2265009873.SGD","LU0353189680.USD","SG9999014898.SGD","LU2552382132.HKD","NVOX","LU1778281490.HKD","LU2362540622.SGD","LU1791710582.SGD","LU0353189763.USD","LU2112291526.USD","IE00BFSS8Q28.SGD","LU1670627923.USD","BK4588","LU0234572021.USD","LU2023251221.USD","SG9999018857.SGD","LLYX","TMED","LU1232071149.USD","LU1854104046.USD","LU1291159041.SGD","LU2108987350.USD","IE00BSNM7G36.USD","LU1267930730.SGD","IYH","IE00B4JS1V06.HKD","LU0251132253.USD","LU1066051498.USD","LU0965509283.SGD","LU0820561818.USD","LU0965509101.SGD","LU2360032135.SGD","LU0289739699.SGD","LU1280957306.USD","LU2089284900.SGD","IE00B19Z8W00.USD","XBI","LU2362541273.HKD","LU0545039389.USD","IE00BWXC8680.SGD","LU0048584097.USD","IE00BZ1G4Q59.USD","LU1674673428.USD","LU2462157665.USD","LU2462591350.SGD","LU0672654240.SGD","LU2168564222.USD","MHIP","LU2237443465.HKD","IE0004445239.USD","LU2237438978.USD","THNR","IE00B1XK9C88.USD","LU1267930227.SGD","LU1003077747.HKD","LU2211815571.USD","LU2756315318.SGD","LU0342679015.USD","LU0708995401.HKD","LU2271345857.HKD","IE00B19Z9Z06.USD","UNHU","LU2471134952.CNY","PPH","CURE","ELIL","LU2236285917.USD","LU2462591277.SGD","ELIS","LU1732800096.USD","LU2237443549.SGD","LU1119994496.HKD","LU1814569148.SGD","LU0211328371.USD","JDOC","IE00B19Z3581.USD","LU0006306889.USD","LU1868836914.USD","LU0011850046.USD","GDOC","LU1670628061.USD","LU1035775433.USD","HRTS","LU0965509010.AUD","LU1069344957.HKD","IE00BFXG1179.USD","BK4533","IE00B894F039.SGD","LU2023250504.SGD","LU0417517546.SGD","AGNG","LU2456880835.USD","IE00B2B36J28.USD","LU0316494557.USD","MEDI","GB00BDT5M118.USD","LU1548497426.USD","LU1917777945.USD","LU0795875169.SGD","LU0795875086.SGD","LU0466842654.USD","LU0149725797.USD","LU0162691827.USD","IE00BJJMRZ35.SGD","LU1093756325.SGD","LU0823434583.USD","LU1069347547.HKD","UNH","LU2023250330.USD","IHE","LU1934455277.USD","LU2491049909.HKD","LU1791710400.SGD","LU2471134879.HKD","LU0471298694.HKD","LU2746668461.USD","LU0496365809.HKD","LU0949170772.SGD","LU1868836591.USD","FHLC","LU0094547139.USD","LU0096364046.USD","BK4532","IE00B7KXQ091.USD","LU0210536198.USD","SG9999002224.SGD","LU2750360641.GBP","IE00BKPKM429.USD","SG9999014880.SGD","SG9999015952.SGD","LU1551013342.USD","LU1037948541.HKD","LU2125154778.USD","LU0889565916.HKD","LU0203345920.USD","SGXZ57979304.SGD","LU1934455194.USD","NVO","LU2168564065.EUR","IE00BKVL7J92.USD","LU1988902786.USD","IE00B19Z9505.USD","LU0187121727.USD","LU2168563687.JPY","LU0786609619.USD","LU2362541513.USD","LU0154236417.USD","LU2954938101.SGD","LU1323610961.USD","SG9999014914.USD","LU0823434740.USD","LU1854103824.USD","LU0683600562.USD","LU0661504455.SGD","LU1153585028.USD","UNHG","LU2237443622.USD","LU1127390331.HKD","LU0211326755.USD","LU2361045086.USD","LU2242649171.HKD","LU2347655156.SGD","SG9999015986.USD","LU1023059063.AUD","LU1551013425.SGD","LU0133085943.USD","BK4516","SG9999015945.SGD","SG9999002232.USD","SG9999001176.SGD","IE0002270589.USD","LU0689472784.USD","LU2471134523.USD","LU2750360997.AUD","SG9999001176.USD","LU2491050154.USD","LU2111349929.HKD","LU1720051017.SGD","LU2746668974.SGD","LU2168564495.EUR","LU1261432733.SGD","LU0079474960.USD","LU0976567544.SGD","LU2028103732.USD","LU0077335932.USD","LU0203347892.USD","LU2168564149.EUR","IE0009355771.USD","BK4534","LLII","LU0029864427.USD","LABU","LU1868837300.USD","LU0052756011.USD","LU2279689827.SGD","LU0964807845.USD","LU2089283258.USD","IE00B19Z3B42.SGD","LU0053666078.USD","LU1066051225.USD","LU0128525929.USD","LU0354030438.USD","LU0310800965.SGD","SGXZ31699556.SGD","LU0310799852.SGD","SG9999017495.SGD","LU2417539215.USD","LU2357305700.SGD","IE00BZ9MQY76.HKD","BK4581","LU0114720955.EUR","LU1732799900.SGD","IE0002141913.USD","LU0882574139.USD","LU0072461881.USD","LU0310800379.SGD","LU0320765992.SGD","SG9999013999.USD","LU2491050071.SGD","LU0456855351.SGD","LU1037948897.HKD","LU2999663052.SGD","LU0820561909.HKD","LU2471134796.USD","LU1934455863.HKD","LU0174119429.USD","IE00B4R5TH58.HKD","LU0965508806.USD","LU0238689110.USD","PJP","LU0211326839.USD","LU0143551892.USD","LLY","LU2756315664.SGD","LU0640476718.USD","LU1267930490.SGD","LU0823416689.USD","BK4585","LU1914381329.SGD","LU1496350502.SGD","LU0323591593.USD","SGXZ99366536.SGD","LU1804176565.USD","SGXZ51526630.SGD","LU1989771016.USD","IE0005OL40V9.USD","LU0345770993.USD","LU0354030511.USD","LU0385154629.USD","IE00B3T34201.USD","IE00BKDWB100.SGD","LU0225283273.USD","LU0912757837.SGD","IE00BFTCPJ56.SGD","LU2324357040.USD","UNHW","LU1629891620.HKD","LU2125154935.USD","LU0158827781.USD","LU0107464264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654713590","title":"美国FDA批准大冢制药ADHD创新药Simtriyo上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2654713590","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654713590?lang=zh_cn&edition=full","pubTime":"2026-07-28 15:21","pubTimestamp":1785223299,"startTime":"0","endTime":"0","summary":"7月27日，美国食品药品监督管理局正式批准日本大冢制药公司研发的每日一次缓释胶囊Simtriyo上市，用于治疗6岁及以上患者的注意缺陷多动障碍。该药物是全球首个获批的去甲肾上腺素、多巴胺和血清素重摄取抑制剂。由于美国FDA将Simtriyo归类为具有多巴胺能效应的兴奋剂，该药物在美国正式发售前必须通过DEA为期最长三个月的标准审查。　　大冢制药于2017年斥资收购Neurovance公司并取得该药物的研发权益。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-28/doc-inikivty8141592.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["ADHD","BK4585","ABVC","BK4139","LABU","LNGR","MEDX","IBBQ","IPOS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654040599","title":"医疗健康基金Eaton Vance二季度大幅减持Zoetis，持仓占比下降45.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654040599","media":"环球市场播报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654040599?lang=zh_cn&edition=full","pubTime":"2026-07-28 03:46","pubTimestamp":1785181560,"startTime":"0","endTime":"0","summary":"Eaton Vance全球医疗健康科学基金在2026年第二季度对其投资组合进行了重大调整，最引人注目的是将Zoetis Inc的持仓削减了45.48%。根据最新的SEC 13F文件披露，截至2026年2月28日，该基金持有Zoetis约200，609股，价值约2571万美元。此次大幅减持Zoetis的背景是该公司近期业绩表现面临一定压力。在2026年第一季度，Zoetis在美国市场的伴侣动物业务收入下降了8%。此次第二季度的减持动作表明，基金经理可能在Zoetis业绩增速放缓、竞争加剧的背景下，选择降低对该公司的风险敞口。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-28/doc-inikhuhv0533857.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LABU","BK4585","BK4581","XLV","159760","BK4550","XBI","VHT","IXJ","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654046711","title":"恒瑞医药(01276.HK)：HR-4375 注射液用于治疗胰腺癌适应症获得美国 FDA授予的孤儿药资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2654046711","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654046711?lang=zh_cn&edition=full","pubTime":"2026-07-27 22:56","pubTimestamp":1785164185,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","LABU","HR","BK4225","BK4585","BK4203","SRET"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654046031","title":"医疗数据解决方案提供商Healthcare Triangle成立Purpose Health，加速AI医疗商业化与股东回报","url":"https://stock-news.laohu8.com/highlight/detail?id=2654046031","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654046031?lang=zh_cn&edition=full","pubTime":"2026-07-27 22:52","pubTimestamp":1785163920,"startTime":"0","endTime":"0","summary":"美国医疗数据解决方案提供商Healthcare Triangle今日宣布成立全资子公司Purpose Health，并任命资深医疗科技与AI服务领袖Sumit Ganguli为董事长兼首席执行官，旨在把握数十亿美元规模的医疗AI市场机遇，加速AI需求变现与股东回报。Healthcare Triangle首席财务官表示，Ganguli在医疗科技服务领域构建和扩展业务的履历，使他成为领导Purpose Health的理想人选，其深厚的领域专长及医疗生态关系将加速公司向客户交付可复用的AI解决方案。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-27/doc-inikhisw9736005.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["TPFC","159891","BK4581","DIVG","IPKW","CHAT","BK4167","HCTI","LCOW","STXD","BK4585","LGCF","SYLD","AGIX","QTOC","MYLD","VTHR","PKW","BK4588","XLV","SHRY","AIPO","COWZ","IDVY","ARTY","XBI","LABU","LYLD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654677046","title":"FDA委员会投票支持六种肽类药物纳入复方路径，Enhanced公司表示欢迎","url":"https://stock-news.laohu8.com/highlight/detail?id=2654677046","media":"环球市场播报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654677046?lang=zh_cn&edition=full","pubTime":"2026-07-27 22:31","pubTimestamp":1785162660,"startTime":"0","endTime":"0","summary":"临床定制化健康产品公司Enhanced Group Inc．今日发表声明，对FDA药学复方咨询委员会上周的投票结果表示赞赏。委员会仅否决了将Emideltide列入清单的提议。Enhanced公司首席执行官表示，这是行业所需的监管方向，为肽类药物提供了从灰色市场走向规范监督的路径。Enhanced公司自成立以来，一直通过许可的复方药房运营，其临床基础设施已就位。若FDA最终采纳委员会建议并完成规则制定流程，公司可迅速通过合规处方渠道提供相关服务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-27/doc-inikhisv2949265.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654013089","title":"恒瑞医药：SHR-4375注射液治疗胰腺癌适应症获FDA孤儿药资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2654013089","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654013089?lang=zh_cn&edition=full","pubTime":"2026-07-27 16:53","pubTimestamp":1785142380,"startTime":"0","endTime":"0","summary":"7月27日，恒瑞医药（600276/01276）发布公告，公司产品SHR-4375注射液用于治疗胰腺癌适应症获得美国食品药品监督管理局（FDA）授予的孤儿药资格认定。此资格将使公司在产品研发、注册及商业化等方面享受美国的政策支持。SHR-4375注射液是公司自主研发的抗体药物偶联物，已推进至国内临床试验的Ⅱ期阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607273822155855.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607273822155855.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2148510915.USD","LU2097828714.EUR","LU1969619763.USD","LU1655091616.SGD","BK0060","BK1191","LU0405327148.USD","LU1820825898.SGD","LU1023057109.AUD","LU1255011170.USD","LU1997245094.SGD","BK4585","600276","LU1997245177.USD","LU2495084118.USD","LU2289578879.USD","01276","LU1328615791.USD","LU2097828474.EUR","LU0359201612.USD","BK0188","LU2580892862.HKD","BK0183","LU1064131003.USD","LU2580892789.USD","BK4588","BK0012","LU0359202008.SGD","LU2543165471.USD","LU1580142542.USD","LU1146622755.USD","LU2097828805.USD","LU2488822045.USD","LU2328871848.SGD","LU1781817850.SGD","LABU","LU0405327494.USD","LU2097828557.USD","LU1064130708.USD","BK0028","BK0196","LU0359201885.HKD","BK0239","LU2097828631.EUR","LU1997244956.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654587013","title":"恒瑞医药：产品SHR - 4375注射液获美国FDA孤儿药资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2654587013","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654587013?lang=zh_cn&edition=full","pubTime":"2026-07-27 16:41","pubTimestamp":1785141697,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LABU","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654906570","title":"健友股份(603707.SH)：门冬胰岛素注射液获得美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2654906570","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654906570?lang=zh_cn&edition=full","pubTime":"2026-07-27 15:36","pubTimestamp":1785137802,"startTime":"0","endTime":"0","summary":"智通财经APP讯，健友股份(603707.SH)发布公告，公司全资子公司Emerge Bioscience Pte.Ltd.(以下简称“Emerge”)于近日收到美国食品药品监督管理局(以下简称“美国FDA”)签发的门冬胰岛素注射液的BLA批准信(BLA号：761497/Original1)。本次门冬胰岛素注射液获得美国FDA批准，将进一步提升公司产品的国际影响力，丰富公司国际市场产品线，提高公司国际市场竞争力。若后续推进美国市场上市销售，有望对公司经营业绩产生积极影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1472526.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LABU","BK0186","BK0239","BK4588","BK4585","603707","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654090546","title":"健友股份：子公司门冬胰岛素注射液获美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2654090546","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654090546?lang=zh_cn&edition=full","pubTime":"2026-07-27 15:35","pubTimestamp":1785137700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LABU","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653608296","title":"美国最大营利性医院HCA Healthcare第二季度业绩超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2653608296","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653608296?lang=zh_cn&edition=full","pubTime":"2026-07-24 20:30","pubTimestamp":1784896200,"startTime":"0","endTime":"0","summary":"美国最大营利性医院运营商HCA Healthcare公布第二财季业绩，营收和利润均超出市场预期，但公司同步下调了全年盈利指引，主要受到患者支付结构变化带来的约4亿美元税前利润冲击。调整后EBITDA为40.27亿美元，同比增长4.6%。管理层表示，患者倾向于选择急诊而非择期手术，反映出消费行为的变化。调整后EBITDA预期下调至154亿至161亿美元。　　尽管季度业绩超预期且公司估值指标仍显示合理水平，但全年指引下调使投资者对支付结构变化带来的持续影响保持警惕。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-24/doc-iniixfxy9332532.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4504","LU2355687059.USD","XBI","LU0985489474.SGD","LU0114720955.EUR","BK4185","LU0648001328.SGD","LU0882574055.USD","LU1489326972.SGD","LU0868494617.USD","LU1084165304.USD","LU0203345920.USD","LU0211328371.USD","LU0878866978.SGD","LU0708994859.HKD","IE00B775SV38.USD","SG9999014039.USD","IE00B3S45H60.SGD","LU0980610538.SGD","XLV","BK4585","LU0130102774.USD","LU0310799852.SGD","LU1201861249.SGD","SG9999014013.SGD","LU0310800379.SGD","BK4588","SG9999014005.SGD","HCA","LU1150488135.SGD","IHF","LU1267930573.SGD","LU0211327993.USD","BK4581","LU2244417387.USD","LU0203347892.USD","LU1267930490.SGD","LU0128525929.USD","LU1261432733.SGD","LU1150488218.USD","SG9999014021.USD","LU0433182093.SGD","LU0068578508.USD","LU0187121727.USD","LU1119994496.HKD","LABU","LU0029864427.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653700110","title":"海正药业(600267.SH)子公司制剂产品磷酸氟达拉滨注射液获得美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2653700110","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653700110?lang=zh_cn&edition=full","pubTime":"2026-07-24 16:53","pubTimestamp":1784883217,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海正药业(600267.SH)发布公告，近日，公司全资子公司海正药业(杭州)有限公司(简称“海正杭州公司”)收到美国食品药品监督管理局(简称“美国FDA”)的通知，海正杭州公司向美国FDA申报的磷酸氟达拉滨注射液的新药简略申请(ANDA，即美国仿制药申请)已获得批准，意味着海正杭州公司可以在美国市场销售该产品。据悉，磷酸氟达拉滨注射液是一种核苷代谢抑制剂，适应症为：作为联合治疗方案的组成药物，用于治疗成人B细胞慢性淋巴细胞白血病(CLL);用于对既往接受至少1种含烷化剂的治疗方案治疗无效，或在治疗过程中出现疾病进展的成人B细胞慢性淋巴细胞白血病患者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471931.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK0239","BK0188","BK0060","LABU","BK4588","600267","BK0028"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0846},{"period":"1month","weight":-0.2038},{"period":"3month","weight":0.3079},{"period":"6month","weight":0.4002},{"period":"1year","weight":2.77},{"period":"ytd","weight":0.457}],"compareEarnings":[{"period":"1week","weight":-0.024},{"period":"1month","weight":-0.0156},{"period":"3month","weight":0.015},{"period":"6month","weight":0.0542},{"period":"1year","weight":0.1483},{"period":"ytd","weight":0.0697}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.020883},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.009536},{"month":3,"riseRate":0.181818,"avgChangeRate":-0.135885},{"month":4,"riseRate":0.454545,"avgChangeRate":-0.001739},{"month":5,"riseRate":0.545455,"avgChangeRate":0.013816},{"month":6,"riseRate":0.75,"avgChangeRate":0.158596},{"month":7,"riseRate":0.583333,"avgChangeRate":0.032682},{"month":8,"riseRate":0.636364,"avgChangeRate":-0.004065},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.0652},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.047038},{"month":11,"riseRate":0.818182,"avgChangeRate":0.199161},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.032237}],"exchange":"ARCA","name":"三倍做多标普生物-Direxion","nameEN":"Direxion Daily S&P Biotech Bull 3x Shares"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"三倍做多标普生物-Direxion(LABU)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供三倍做多标普生物-Direxion(LABU)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"三倍做多标普生物-Direxion,LABU,三倍做多标普生物-Direxion股票,三倍做多标普生物-Direxion股票老虎,三倍做多标普生物-Direxion股票老虎国际,三倍做多标普生物-Direxion行情,三倍做多标普生物-Direxion股票行情,三倍做多标普生物-Direxion股价,三倍做多标普生物-Direxion股市,三倍做多标普生物-Direxion股票价格,三倍做多标普生物-Direxion股票交易,三倍做多标普生物-Direxion股票购买,三倍做多标普生物-Direxion股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"三倍做多标普生物-Direxion(LABU)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供三倍做多标普生物-Direxion(LABU)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}